Systemic therapy in melanoma

✍ Scribed by Faith E. Nathan; Michael J. Mastrangelo

• Book ID: 101271877
• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 59 KB
• Volume: 14
• Category: Article
• ISSN: 8756-0437
• DOI: 10.1002/(sici)1098-2388(199806)14:4<319::aid-ssu8>3.0.co;2-5

✦ Synopsis

The patient with surgically incurable melanoma presents a difficult problem for the medical oncologist. Single chemotherapeutic agents at conventional doses produce bona fide but infrequent remissions. The most active single agent for the treatment of metastatic melanoma is dacarbazine (DTIC). Until recently, combinations of drugs yielded no real improvement over treatment with the individual components. The combination of DTIC + carmustine (BCNU) + cisplatin + tamoxifen (the "Dartmouth regimen") appears to be more effective than DTIC alone, but prospective randomized trials comparing the two are still in progress. The contribution of tamoxifen to the observed results continues to be evaluated. Biological agents, such as interferon and interleukin-2, have lower overall response rates compared to chemotherapy regimens, but response duration appears to be longer. Chemotherapy combined with biotherapy offers the promise of higher response rates and long-term durable remissions. The results from high-dose regimens that use autologous bone marrow or peripheral stem cell support have not been sufficient to justify the added toxicity. Although advanced melanoma often is not curable with systemic therapy, the considered use of currently available regimens can induce clinically significant remissions and, possibly, prolong life in some patients. Semin.